Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Marries Its Pharmacogenomics With Biogen s Drug Targets

NEW YORK, Feb. 1 - Genaissance Pharmaceuticals and Biogen struck a deal to combine pharmacogenomic testing and drug development, the two companies said on Friday.


The aim of the deal is to pair pharmacogenomic tests with new drug targets and drugs currently in development at Biogen, and ultimately market the two in tandem.


Through the partnership, Genaissance will get an upfront cash payment, research funds, and milestone payments. The company is also eligible for downstream payments based on successful development.


Financial details were not disclosed.


The partnership will make use of Genaissance's HAP technology in order to characterize haplotypes and link these with drug responses. The company will process samples from Biogen's clinical work.


Genaissance says it has a cache of almost 100,000 haplotypes from more than 5,400 genes, and intends to discover haplotypes for all human genes.


The New Haven, Conn.-based firm began clinical trials last year to connect haplotype profiles with patient drug response to a set of cholesterol-lowering drugs. It also plans to develop its own drugs.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.